Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today will provide a further update on its autoimmune program, and its plans for initiating clinical development in genetically defined forms of B-cell lymphoma, in a presentation at the Stifel Nicolaus 2013 Healthcare Conference in Boston.
Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera Pharmaceuticals, and Jim Geraghty, Chairman of Idera’s Board of Directors, will highlight several ways in which the company has recently strengthened its business. They will provide an update on progress in the company's ongoing Phase 2 trial of its lead candidate, IMO-8400, a TLR 7, 8 and 9 antagonist, present the path forward for the company’s recently announced B-cell lymphoma program, and describe the company’s plans to expand its pipeline with the development of additional preclinical compounds.
Idera’s B-cell lymphoma program leverages an emerging scientific understanding of the central role that Toll-like Receptors (TLRs) 7 and 9 play in several forms of B-cell lymphoma with specific mutations, including activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), Waldenström’s macroglobulinemia, and others. The company’s proprietary TLR antagonists have been shown to effectively inhibit TLR 7 and 9 in preclinical studies and in a completed Phase 2 clinical proof-of-concept study in psoriasis.
Existing safety data on IMO-8400 would enable Idera to submit an IND for IMO-8400 in Q4 2013, and initiate a Phase 1/2 clinical trial of IMO-8400 in lymphoma patients with these specific mutations in Q1 2014. The company is currently considering its options for financing this program, and would begin clinical development following the successful completion of these plans.“We are making rapid progress in turning emerging findings in certain forms of B-cell lymphoma into a clinical development program, and hope to begin dosing the first patients early next year,” Dr. Agrawal said. “Despite notable advances, success in treating B-cell lymphoma has been limited, and patients with certain genetically defined mutations remain in desperate need of new treatments. We believe the limited number and severe condition of these patients may support regulatory designations that would allow us to advance these programs rapidly.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts